New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology

European Journal of Pharmacology

Volumn 809, Issue , 2017, Pages 111-121

  Zádor, Ferenc ^b   Király, Kornél ^a   Váradi, András ^a   Balogh, Mihály ^a   Fehér, Ágnes ^a   Kocsis, Dóra ^b   Erdei, Anna I ^b   Lackó, Erzsébet ^a   Zádori, Zoltán S ^a   Hosztafi, Sándor ^a   Noszál, Béla ^a   Riba, Pál ^a   Benyhe, Sándor ^b   Fürst, Susanna ^a   Al Khrasani, Mahmoud ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

Isolated organs; Mouse tail flick assay; Naltrexone 14 O sulfate; Opioid receptor binding

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NALTREXONE 14 O SULFATE; OPIATE AGONIST; UNCLASSIFIED DRUG; ANALGESIC AGENT; NALTREXONE-14-O-SULFATE; NARCOTIC ANTAGONIST; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VITRO STUDY; ISOLATED ORGAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TAIL FLICK TEST; VAS DEFERENS; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; METABOLISM; MOUSE; SYNTHESIS; WISTAR RAT;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; CHEMISTRY TECHNIQUES, SYNTHETIC; COLON; MALE; MICE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, OPIOID; VAS DEFERENS;

EID: 85020107892     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.05.024     Document Type: Article

References (51)

1. Aceto, M.D., Harris, L.S., Bowman, E.R., Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity. Eur. J. Pharmacol. 338 (1997), 215–223.
2. Andersson, M., Björkhem-Bergman, L., Ekström, L., Bergqvist, L., Lagercrantz, H., Rane, A., Beck, O., Detection of morphine-3-sulfate and morphine-6-sulfate in human urine and plasma, and formation in liver cytosol. Pharmacol. Res. Perspect., 2, 2014, e00071.
3. Arunlakshana, O., Schild, H.O., Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 14 (1959), 48–58.
4. Barnett, V., Twycross, R., Mihalyo, M., Wilcock, A., Opioid antagonists. J. Pain. Symptom Manag. 47 (2014), 341–352.
5. Benyhe, S., Farkas, J., Tóth, G., Wollemann, M., Met5-enkephalin-Arg6-Phe7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J. Neurosci. Res. 48 (1997), 249–258.
6. Brown, D.R., Goldberg, L.I., The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24 (1985), 181–191.
7. Chen, Y., Mestek, A., Liu, J., Hurley, J.A., Yu, L., Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol. Pharmacol. 44 (1993), 8–12.
8. Codd, E.E., Shank, R.P., Schupsky, J.J., Raffa, R.B., Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J. Pharmacol. Exp. Ther. 274 (1995), 1263–1270.
9. Edgerton, L., Loven, B., Clinical inquiries. What are the adverse effects of prolonged opioid use in patients with chronic pain?. J. Fam. Pract. 60 (2011), 288–289.
10. Evans, C.J., Keith, D.E., Morrison, H., Magendzo, K., Edwards, R.H., Cloning of a delta opioid receptor by functional expression. Science 58 (1992), 1952–1955.
11. Fürst, S., Transmitters involved in antinociception in the spinal cord. Brain Res. Bull. 48 (1999), 129–141.
12. Fürst, S., Riba, P., Friedmann, T., Tímar, J., Al-Khrasani, M., Obara, I., Makuch, W., Spetea, M., Schütz, J., Przewlocki, R., Przewlocka, B., Schmidhammer, H., Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J. Pharmacol. Exp. Ther. 312 (2005), 609–618.
13. Garner, H.R., Burke, T.F., Lawhorn, C.D., Stoner, J.M., Wessinger, W.D., Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement. J. Pharmacol. Exp. Ther. 282 (1997), 1253–1261.
14. Holzer, P., Opioid receptors in the gastrointestinal tract. Regul. Pept. 155 (2009), 11–17.
15. Khalefa, B.I., Mousa, S.A., Shaqura, M., Lackó, E., Hosztafi, S., Riba, P., Schäfer, M., Ferdinandy, P., Fürst, S., Al-Khrasani, M., Peripheral antinociceptive efficacy and potency of a novel opioid compound 14-O-MeM6SU in comparison to known peptide and non-peptide opioid agonists in a rat model of inflammatory pain. Eur. J. Pharmacol. 713 (2013), 54–57.
16. Kiefer, F., Mann, K., New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur. J. Pharmacol. 526 (2005), 163–171.
17. Kieffer, B.L., Befort, K., Gaveriaux-Ruff, C., Hirth, C.G., The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. USA 89 (1992), 12048–12052.
18. Kiraly, K., Caputi, F.F., Hanuska, A., Kató, E., Balogh, M., Köles, L., Palmisano, M., Riba, P., Hosztafi, S., Romualdi, P., Candeletti, S., Ferdinandy, P., Fürst, S., Al-Khrasani, M., A new potent analgesic agent with reduced liability to produce morphine tolerance. Brain Res. Bull. 117 (2015), 32–38.
19. Kosterlitz, H.W., Watt, A.J., Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. Chemother. 33 (1968), 266–276.
20. Kurogi, K., Chen, M., Lee, Y., Shi, B., Yan, T., Liu, M.-Y., Sakakibara, Y., Suiko, M., Liu, M.-C., Sulfation of buprenorphine, pentazocine, and naloxone by human cytosolic sulfotransferases. Drug Metab. Lett. 6 (2012), 109–115.
21. Kurogi, K., Chepak, A., Hanrahan, M.T., Liu, M.-Y., Sakakibara, Y., Suiko, M., Liu, M.-C., Sulfation of opioid drugs by human cytosolic sulfotransferases: metabolic labeling study and enzymatic analysis. Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 62 (2014), 40–48.
22. Lacko, E., Varadi, A., Rapavi, R., Zador, F., Riba, P., Benyhe, S., Borsodi, A., Hosztafi, S., Timar, J., Noszal, B., Furst, S., Al-Khrasani, M., A novel µ-opioid receptor ligand with high in vitro and in vivo agonist efficacy. Curr. Med. Chem. 19 (2012), 4699–4707.
23. Lacko, E., Riba, P., Giricz, Z., Varadi, A., Cornic, L., Balogh, M., Kiraly, K., Cseko, K., Mousa, S.A., Hosztafi, S., Schafer, M., Zadori, Z.S., Helyes, Z., Ferdinandy, P., Furst, S., Al-Khrasani, M., New morphine analogs produce peripheral antinociception within a certain dose range of their systemic administration. J. Pharmacol. Exp. Ther. 359 (2016), 171–181.
24. Lazar, S., Jabbouri, S., Moisand, C., Noël-Hocquet, S., Meunier, J., Ropars, C., Guillaumet, G., Synthesis and biological activity of the phosphate and sulfate esters of naloxone and naltrexone. Eur. J. Med. Chem. 29 (1994), 45–53.
25. Lewanowitsch, T., Irvine, R.J., Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal. Eur. J. Pharmacol. 445 (2002), 61–67.
26. Linder, C., Fishman, J., Narcotic antagonists. 1. isomeric sulfate and acetate esters of naloxone (N-allylnoroxymorphone). J. Med. Chem. 16 (1973), 553–556.
27. Mansour, A., Fox, C., Akil, H., Watson, S., Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995), 22–29.
28. Mehta, N., O'Connell, K., Giambrone, G., Baqai, A., Diwan, S., Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. Postgrad. Med, 2016.
29. Minami, M., Toya, T., Katao, Y., Maekawa, K., Nakamura, S., Onogi, T., Kaneko, S., Satoh, M., Cloning and expression of a cDNA for the rat kappa-opioid receptor. FEBS Lett. 329 (1993), 291–295.
30. Mori, M.-A., Oguri, K., Yoshimura, H., Shimomura, K., Kamata, O., Ueki, S., Chemical synthesis and analgesic effect of morphine ethereal sulfates. Life Sci. Pt. 1: Physiol. Pharmacol. 11 (1972), 525–533.
31. Negus, S.S., Pasternak, G.W., Koob, G.F., Weinger, M.B., Antagonist effects of beta-funaltrexamine and naloxonazine on alfentanil-induced antinociception and muscle rigidity in the rat. J. Pharmacol. Exp. Ther., 264, 1993.
32. Nevin, S.T., Kabasakal, L., Otvös, F., Töth, G., Borsodi, A., Binding characteristics of the novel highly selective delta agonist, [3H]IIe5,6deltorphin II. Neuropeptides 26 (1994), 261–265.
33. Oktem, H.A., Moitra, J., Benyhe, S., Toth, G., Lajtha, A., Borsodi, A., Opioid receptor labeling with the chloromethyl ketone derivative of [3H]Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO) II: covalent labeling of mu opioid binding site by 3H-Tyr-D-Ala-Gly-(Me)Phe chloromethyl ketone. Life Sci. 48 (1991), 1763–1768.
34. Oldham, W.M., Hamm, H.E., Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 9 (2008), 60–71.
35. Pol, O., Planas, E., Puig, M.M., Peripheral effects of naloxone in mice with acute diarrhea associated with intestinal inflammation. J. Pharmacol. Exp. Ther. 272 (1995), 1271–1276.
36. Przewłocki, R., Przewłocka, B., Opioids in chronic pain. Eur. J. Pharmacol. 429 (2001), 79–91.
37. Ray, L.A., Chin, P.F., Miotto, K., Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol. Disord. Drug Targets 9 (2010), 13–22.
38. Rónai, A.Z., Gráf, L., Székely, J.I., Dunai-Kovács, Z., Bajusz, S., Differential behaviour of LPH-(61–91)-peptide in different model systems: comparison of the opioid activities of LPH-(61–91)-peptide and its fragments. FEBS Lett. 74 (1977), 182–184.
39. Schmauss, C., Yaksh, T.L., In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J. Pharmacol. Exp. Ther., 228, 1984.
40. Sim, L.J., Selley, D.E., Childers, S.R., In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. USA 92 (1995), 7242–7246.
41. Spetea, M., Schmidhammer, H., Recent advances in the development of 14-alkoxy substituted morphinans as potent and safer opioid analgesics. Curr. Med. Chem. 19 (2012), 2442–2457.
42. Székely, J.I., Dunai-Kovács, Z., Miglécz, E., Rónai, A.Z., Bajusz, S., In vivo antagonism by naloxone of morphine, beta-endorphin and a synthetic enkephalin analog. J. Pharmacol. Exp. Ther., 207, 1978.
43. Szücs, M., Borsodi, A., Bogdány, A., Gaál, J., Batke, J., Tóth, G., Detailed analysis of heterogeneity of [3H]naloxone binding sites in rat brain synaptosomes. Neurochem. Res. 12 (1987), 581–587.
44. Takemori, A.E., Portoghese, P.S., Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Eur. J. Pharmacol. 104 (1984), 101–104.
45. Traynor, J.R., Nahorski, S.R., Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47 (1995), 848–854.
46. Tulunay, F.C., Takemori, A.E., The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J. Pharmacol. Exp. Ther. 190 (1974), 395–400.
47. Váradi, A., Gergely, A., Béni, S., Jankovics, P., Noszál, B., Hosztafi, S., Sulfate esters of morphine derivatives: synthesis and characterization. Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 42 (2011), 65–72.
48. Walker, E.A., Makhay, M.M., House, J.D., Young, A.M., In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J. Pharmacol. Exp. Ther., 271, 1994.
49. Yasuda, K., Raynor, K., Kong, H., Breder, C.D., Takeda, J., Reisine, T., Bell, G.I., Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. Natl. Acad. Sci. USA 90 (1993), 6736–6740.
50. Yuan, C.S., Foss, J.F., Moss, J., Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur. J. Pharmacol. 276 (1995), 107–111.
51. Zacny, J.P., Wroblewski, K., Coalson, D.W., Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers. Psychopharmacology 232 (2015), 63–73.